BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17454614)

  • 1. A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation.
    Marková J; Průková D; Volková Z; Schwarz J
    Leuk Lymphoma; 2007 Mar; 48(3):636-9. PubMed ID: 17454614
    [No Abstract]   [Full Text] [Related]  

  • 2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
    Bartels S; Lehmann U; Büsche G; Schlue J; Hussein K; Debatin D; Karcher A; Andrulis M; Schirmacher P; Kreipe H
    Ann Hematol; 2015 Jul; 94(7):1255-6. PubMed ID: 25865944
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
    Reading NS; Lim MS; Elenitoba-Johnson KS
    Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.
    Le Bars H; Boulland ML; Bareau B; Grosbois B; Corolleur M; Lamy T; Fardel O
    Int J Lab Hematol; 2010 Aug; 32(4):458-60. PubMed ID: 20331762
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chip-based digital polymerase chain reaction technology is useful for monitoring the JAK2 V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
    Furuya D; Moriai M; Murai R; Moriai R; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Lab Hematol; 2019 Oct; 41(5):e113-e116. PubMed ID: 30903743
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
    Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
    Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advance of study on JAK2 V617F in myeloproliferative disorders -- review].
    Xu YY; Li HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):238-42. PubMed ID: 19236788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
    Shao DH; Liang GW; He ML; Cao QY
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locked nucleic acid probes for enhanced detection of FLT3 D835/I836, JAK2 V617F and NPM1 mutations.
    Warshawsky I; Mularo F
    J Clin Pathol; 2011 Oct; 64(10):905-10. PubMed ID: 21666141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence for amplification of V617F JAK2 in myeloproliferative disorders.
    Jones AV; Bunyan DJ; Cross NC
    Leukemia; 2007 Dec; 21(12):2561-3. PubMed ID: 17611555
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
    Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
    Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.